Connor, Clark & Lunn Investment Management (CC&L)
RPTX

Connor, Clark & Lunn Investment Management (CC&L)’s Repare Therapeutics RPTX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25,826
Closed -$122K – 1650
2024
Q1 		$122K Buy
25,826
+9,097
+54% +$58.3K ﹤0.01% 1453
2023
Q4 		$122K Buy
16,729
+1,810
+12% +$10.1K ﹤0.01% 1305
2023
Q3 		$180K Buy
14,919
+3,493
+31% +$36.1K ﹤0.01% 1248
2023
Q2 		$121K Buy
+11,426
New +$118K ﹤0.01% 1239

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s RPTX Position: Q2 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Repare Therapeutics (RPTX) in Q2 2024, closing a stake of 25,826 shares — an estimated $122K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in RPTX in Q2 2023 and held it in 4 quarters. The position peaked at $180K in Q3 2023. 61 funds tracked by Wall St. Rank hold RPTX as of Q2 2024.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Repare Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 25,826 Repare Therapeutics shares in Q2 2024, an estimated $122K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Repare Therapeutics in Q2 2023 and held it in 4 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Repare Therapeutics position peaked at $180K in Q3 2023.
  • 61 funds tracked by Wall St. Rank held Repare Therapeutics as of Q2 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2024, filed 9 Aug 2024.